Jadwal Sholat

Memuat jadwal sholat…

Kedokteran & Kesehatan editorial

Open AccessOA2023

Accelerating Alzheimer’s Therapeutic Development: The Past and Future of Clinical Trials

After 30 years, positive phase 3 trials of anti-Aβ antibodies lecanemab and donanemab mark a turning point in Alzheimer’s disease. Boxer and Sperling analyze the key enablers—potent fibrillar amyloid reduction, early-stage patient selection, and biomarker validation—and propose novel trial designs, diversity reforms, and collaborative incentives to accelerate future development.
A. Boxer; R. Sperling· Cell· 2023· DOI 10.1016/j.cell.2023.09.023

The core problem

Alzheimer’s disease (AD) research has entered a new era with the recent positive phase 3 clinical trials of the anti-Aβ antibodies lecanemab and donanemab. These successes follow decades of failed trials and raise a central question: why did it take 30 years to achieve them? The authors, A. Boxer and R. Sperling, argue that the answer lies in three critical advances: the development of potent therapies for reducing fibrillar amyloid, the selection of patients at relatively early stages of disease, and the use of biomarkers of the target pathologies—including amyloid and tau PET—along with insights from past trials. This perspective in Cell reviews the historical arc of AD clinical trials and outlines a forward-looking agenda to develop more efficacious therapies with greater efficiency.

Innovation

As a perspective piece, the article synthesizes evidence from prior clinical trials, biomarker studies, and drug development programs rather than presenting new experimental data. The authors draw on the collective experience of phase 2 and phase 3 trials of anti-amyloid agents, the evolution of amyloid and tau PET imaging, and the lessons learned from negative or inconclusive trials. Their analytical approach identifies the factors that distinguished the recent successful trials—lecanemab and donanemab—from earlier failures, and proposes a framework for accelerating future development through novel trial designs, biomarker integration, and collaborative mechanisms.
Introduction
Alzheimer’s disease (AD) research has entered a new era with the recent positive phase 3 clinical trials of the anti-Aβ antibodies lecanemab and donanemab. These successes follow decades of failed trials and raise a central question: why did it take 30 years to achieve them? The authors, A. Boxer and R. Sperling, argue that the answer lies in three critical advances: the development of potent therapies for reducing fibrillar amyloid, the selection of patients at relatively early stages of disease, and the use of biomarkers of the target pathologies—including amyloid and tau PET—along with insights from past trials. This perspective in Cell reviews the historical arc of AD clinical trials and outlines a forward-looking agenda to develop more efficacious therapies with greater efficiency.

Why it matters

Moving forward, the challenge is to develop more efficacious therapies with greater efficiency. The authors propose several strategies:

- **Novel trial designs**: combination therapies, umbrella protocols (testing multiple drugs within one master protocol), and basket protocols (testing one drug across multiple related conditions) to accelerate clinical development.
- **Diversity and inclusivity**: better representation of trial participants is needed; blood-based biomarkers may help improve access for medically underserved groups.
- **Incentivizing innovation**: public-private partnerships, collaborative mechanisms, and new career paths in academia and industry are critical to build momentum.

The authors conclude that these exciting times require sustained collaboration and structural changes to translate scientific progress into effective therapies for Alzheimer’s disease.

Who should read this

Pembaca Research Digest dan praktisi rumpun ini.

Opening member content…